Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Schiff

Showing results (221-230 of 305) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomePatrick G Morris, Denise D Correa, Joachim Yahalom, et al.
Cancer|July 11, 2019
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872Evanthia Galanis, S Keith Anderson, Erin L Twohy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase II study of protracted daily temozolomide for low-grade gliomas in adultsSantosh Kesari, David Schiff, Jan Drappatz, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Neuro-Oncology|May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumabJeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
Neuro-Oncology|August 24, 2018
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working GroupRaymond Y Huang, Wenya Linda Bi, Michael Weller, et al.
Current Problems in Surgery|September 9, 2004
Brain metastasesMark E Shaffrey, Melike Mut, Anthony L Asher, et al.
Neuro-Oncology|March 15, 2006
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyMichael D Prados, Kathleen Lamborn, W K A Yung, et al.
Annals of Neurology|April 6, 2006
International study on low-grade primary central nervous system lymphomaKristoph Jahnke, Agnieszka Korfel, Brian Patrick O'Neill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant gliomaJohn G Kuhn, Susan M Chang, Patrick Y Wen, et al.
Pageof 31

Showing results (221-230 of 305) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomePatrick G Morris, Denise D Correa, Joachim Yahalom, et al.
Cancer|July 11, 2019
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872Evanthia Galanis, S Keith Anderson, Erin L Twohy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase II study of protracted daily temozolomide for low-grade gliomas in adultsSantosh Kesari, David Schiff, Jan Drappatz, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Neuro-Oncology|May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumabJeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
Neuro-Oncology|August 24, 2018
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working GroupRaymond Y Huang, Wenya Linda Bi, Michael Weller, et al.
Current Problems in Surgery|September 9, 2004
Brain metastasesMark E Shaffrey, Melike Mut, Anthony L Asher, et al.
Neuro-Oncology|March 15, 2006
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyMichael D Prados, Kathleen Lamborn, W K A Yung, et al.
Annals of Neurology|April 6, 2006
International study on low-grade primary central nervous system lymphomaKristoph Jahnke, Agnieszka Korfel, Brian Patrick O'Neill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant gliomaJohn G Kuhn, Susan M Chang, Patrick Y Wen, et al.
Pageof 31